Mast cells as a unique hematopoietic lineage and cell system: From Paul Ehrlich's visions to precision medicine concepts
Open accessThe DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
The origin and functions of mast cells (MCs) have been debated since their description by Paul Ehrlich in 1879. MCs have long been considered 'reactive bystanders' and 'amplifiers' in inflammatory processes, allergic reactions, and host responses to infectious diseases. However, knowledge about the origin, phenotypes and functions of MCs has increased substantially over the past 50 years. MCs are now known to be derived from multipotent hematopoietic progenitors, which, through a process of differentiation and maturation, form a unique hematopoietic lineage residing in multiple organs. In particular, MCs are distinguishable from basophils and other hematopoietic cells by their unique phenotype, origin(s), and spectrum of functions, both in innate and adaptive immune responses and in other settings. The concept of a unique MC lineage is further supported by the development of a distinct group of neoplasms, collectively referred to as mastocytosis, in which MC precursors expand as clonal cells. The clinical consequences of the expansion and/or activation of MCs are best established in mastocytosis and in allergic inflammation. However, MCs have also been implicated as important participants in a number of additional pathologic conditions and physiological processes. In this article, we review concepts regarding MC development, factors controlling MC expansion and activation, and some of the fundamental roles MCs may play in both health and disease. We also discuss new concepts for suppressing MC expansion and/or activation using molecularly-targeted drugs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
IgE and mast cells in allergic disease
Galli, S. J., & Tsai, M. (2012) · Nature Medicine · doi:10.1038/nm.2755 · Cited by 1,799 · cited 10×
“MCs may synthesize and secrete many other types of mediators, such as lipid mediators, cytokines and chemokines, and thereby trigger local and systemic reactions [2-7].”
BackgroundInfluentialSelf-citationValent, P., Akin, C., Arock, M., Brockow, K., Butterfield, J. H., Carter, M. C., Castells, M., Escribano, L., Hartmann, K., Lieberman, P., et al. (2012) · International Archives of Allergy and Immunology · doi:10.1159/000328760 · Cited by 654
Self-citationMetcalfe, D. D. (2008) · Blood · doi:10.1182/blood-2007-11-078097 · Cited by 536
Self-citationMast Cells, Mastocytosis, and Related Disorders
Theoharides, T. C., Valent, P., & Akin, C. (2015) · New England Journal of Medicine · doi:10.1056/nejmra1409760 · Cited by 518
Self-citationWodnar-Filipowicz, A., Heusser, C. H., & Moroni, C. (1989) · Nature · doi:10.1038/339150a0 · Cited by 480 · cited 5×
“wide variety of cytokines, chemokines and growth factors [11, 146-150] and some of these products also have been detected in isolated mouse peritoneal mast cells [11].”
BackgroundInfluentialValent, P., Spanblochl, E., Sperr, W., Sillaber, C., Zsebo, K., Agis, H., Strobl, H., Geissler, K., Bettelheim, P., & Lechner, K. (1992) · Blood · doi:10.1182/blood.v80.9.2237.2237 · Cited by 439
Self-citationGalli, S. J., & Tsai, M. (2010) · European Journal of Immunology · doi:10.1002/eji.201040559 · Cited by 403 · cited 3×
“Similar observations have been made in other models of bacterial infections [116, 188].”
BackgroundResultSelf-citationBodemer, C., Hermine, O., Palmérini, F., Yang, Y., Grandpeix-Guyodo, C., Leventhal, P. S., Hadj-Rabia, S., Nasca, L., Georgin-Lavialle, S., Cohen-Akenine, A., et al. (2010) · Journal of Investigative Dermatology · doi:10.1038/jid.2009.281 · Cited by 397 · cited 2×
“that in pediatric patients, in whom the disease was long believed to be a ́reactive ́ (non-neoplastic) process, the disorder is now regarded as a neoplastic condition, because in most cases activating (somatic or germline) mutations in KIT are detectable [284, 285].”
BackgroundSelf-citationLyons, J. J., Yu, X., Hughes, J. D., Le, Q. T., Jamil, A., Bai, Y., Ho, N., Zhao, M., Liu, Y., O'Connell, M. P., et al. (2016) · Nature Genetics · doi:10.1038/ng.3696 · Cited by 394
Self-citationBonadonna, P., Perbellini, O., Passalacqua, G., Caruso, B., Colarossi, S., Dal Fior, D., Castellani, L., Bonetto, C., Frattini, F., Dama, A., et al. (2009) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2008.11.018 · Cited by 392
Mast cell activation syndrome: Proposed diagnostic criteria
Akin, C., Valent, P., & Metcalfe, D. D. (2010) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2010.08.035 · Cited by 327
Self-citationArock, M., Sotlar, K., Akin, C., Broesby-Olsen, S., Hoermann, G., Escribano, L., Kristensen, T. K., Kluin-Nelemans, H. C., Hermine, O., Dubreuil, P., et al. (2015) · Leukemia · doi:10.1038/leu.2015.24 · Cited by 290
Self-citationCosta, J. J., Demetri, G. D., Harrist, T. J., Dvorak, A. M., Hayes, D. F., Merica, E. A., Menchaca, D. M., Gringeri, A. J., Schwartz, L. B., & Galli, S. J. (1996) · The Journal of Experimental Medicine · doi:10.1084/jem.183.6.2681 · Cited by 268
Self-citationProposed Diagnostic Algorithm for Patients with Suspected Mast Cell Activation Syndrome
Valent, P., Akin, C., Bonadonna, P., Hartmann, K., Brockow, K., Niedoszytko, M., Nedoszytko, B., Siebenhaar, F., Sperr, W. R., Oude Elberink, J. N. G., et al. (2019) · The Journal of Allergy and Clinical Immunology: In Practice · doi:10.1016/j.jaip.2019.01.006 · Cited by 225 · cited 1×
“However, MCs also can undergo activation chronically or locally in a number of inflammatory conditions without clinical signs or symptoms of systemic MC activation, so that MCAS criteria are not fulfilled [170].”
BackgroundSelf-citationSignal Transduction by the High-Affinity Immunoglobulin E Receptor FcεRI: Coupling Form to Function
Nadler, M. J. S., Matthews, S. A., Turner, H., & Kinet, J.-P. (2001) · Advances in Immunology · doi:10.1016/s0065-2776(01)76022-1 · Cited by 203
Lyons, J. J. (2018) · Immunology and Allergy Clinics of North America · doi:10.1016/j.iac.2018.04.003 · Cited by 179
Mast cell mediators in allergic inflammation and mastocytosis
Castells, M. (2006) · Immunology and Allergy Clinics of North America · doi:10.1016/j.iac.2006.05.005 · Cited by 112
Evidence that Meningeal mast cells can worsen stroke pathology in mice.
Arac, A., Grimbaldeston, M. A., Nepomuceno, A. R. B., Olayiwola, O., Pereira, M. P., Nishiyama, Y., Tsykin, A., Goodall, G. J., Schlecht, U., Vogel, H., et al. (2014) · The American Journal of Pathology · doi:10.1016/j.ajpath.2014.06.003 · Cited by 74 · cited 4×
“A similar effect was also described for IL-6 [66-68].”
BackgroundInfluentialMast cells and IgE in defense against venoms: Possible “good side” of allergy?
Galli, S. J., Starkl, P., Marichal, T., & Tsai, M. (2016) · Allergology International · doi:10.1016/j.alit.2015.09.002 · Cited by 73 · cited 1×
“Recently, MCs and their products also have been implicated in the defense of mice against animalderived venoms [210-216].”
BackgroundSelf-citationOmalizumab therapy for mast cell-mediator symptoms in patients with ISM, CM, MMAS, and MCAS
Lemal, R., Fouquet, G., Terriou, L., Vaes, M., Livideanu, C. B., Frenzel, L., Barete, S., Canioni, D., Lhermitte, L., Rossignol, J., et al. (2019) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2019.03.039 · Cited by 70 · cited 1×
“are suffering from severe allergies, MCAS and/or additional aggravating MC conditions (like HAT and/or mastocytosis), application of antibodies removing IgE, such as omalizumab or ligelizumab, or targeting MC tryptase, may represent promising additional approaches [310-314].”
BackgroundSelf-citationAnaphylaxis as a clinical manifestation of clonal mast cell disorders
Matito, A., Alvarez-Twose, I., Morgado, J. M., Sánchez-Muñoz, L., Orfao, A., & Escribano, L. (2014) · Current Allergy and Asthma Reports · doi:10.1007/s11882-014-0450-8 · Cited by 51 · cited 11×
“The features and severity of reactions evoked by MC activation depend on additional factors, such as the type and amounts of mediators released and the number and location of reacting MCs (and other immune cells including basophils) involved in the response [166, 167].”
BackgroundInfluentialSelf-citationHauswirth, A. W., Escribano, L., Prados, A., Nuñez, R., Mirkina, I., Kneidinger, M., Florian, S., Sonneck, K., Vales, A., Schernthaner, G.-H., et al. (2008) · International Journal of Immunopathology and Pharmacology · doi:10.1177/039463200802100404 · Cited by 48
Self-citation
Cited by
The ingenious mast cell: contemporary insights into mast cell behavior and function
Dahlin, J. S., Maurer, M., Metcalfe, D. D., Pejler, G., Sagi‐Eisenberg, R., & Nilsson, G. (2022) · Allergy · doi:10.1111/all.14881 · Cited by 147
Self-citationValent, P., Akin, C., Nedoszytko, B., Bonadonna, P., Hartmann, K., Niedoszytko, M., Brockow, K., Siebenhaar, F., Triggiani, M., Arock, M., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21239030 · Cited by 92
Self-citationValent, P., Hartmann, K., Bonadonna, P., Gülen, T., Brockow, K., Alvarez-Twose, I., Hermine, O., Niedoszytko, M., Carter, M. C., Hoermann, G., et al. (2022) · The Journal of Allergy and Clinical Immunology: In Practice · doi:10.1016/j.jaip.2022.05.007 · Cited by 90
Self-citationGülen, T., Akin, C., Bonadonna, P., Siebenhaar, F., Broesby-Olsen, S., Brockow, K., Niedoszytko, M., Nedoszytko, B., Oude Elberink, H. N. G., Butterfield, J. H., et al. (2021) · The Journal of Allergy and Clinical Immunology: In Practice · doi:10.1016/j.jaip.2021.06.011 · Cited by 83
Self-citationValent, P., Hartmann, K., Schwaab, J., Alvarez-Twose, I., Brockow, K., Bonadonna, P., Hermine, O., Niedoszytko, M., Carter, M. C., Hoermann, G., et al. (2022) · The Journal of Allergy and Clinical Immunology: In Practice · doi:10.1016/j.jaip.2022.03.007 · Cited by 72
Self-citation
Metadata
- Authors
- Valent, P., Akin, C., Hartmann, K., Nilsson, G., Reiter, A., Hermine, O., Sotlar, K., Sperr, W. R., Escribano, L., George, T. I., Kluin-Nelemans, H. C., Ustun, C., Triggiani, M., Brockow, K., Gotlib, J., Orfao, A., Kovanen, P. T., Hadzijusufovic, E., Sadovnik, I., Horny, H.-P., Arock, M., Schwartz, L. B., Austen, K. F., Metcalfe, D. D., & Galli, S. J.
- Venue
- Theranostics
- Publisher
- Ivyspring International Publisher
- Published
- 2020
- Volume
- 10
- Issue
- 23
- Pages
- 10743-10768
- ISSN
- 1838-7640 (ISSN-L)
- OpenAlex
- W3083835573
- Cited by
- 180
- References
- 22
- FWCI
- 7.23
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.